SPDR S&P Biotech ETF
424 hedge funds and large institutions have $5.82B invested in SPDR S&P Biotech ETF in 2019 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 134 increasing their positions, 137 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
424
Holders Change
-27
Holders Change %
-5.99%
% of All Funds
9.22%
Holding in Top 10
15
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.14%
% of All Funds
0.33%
New
45
Increased
134
Reduced
137
Closed
67
Calls
$849M
Puts
$1.85B
Net Calls
-$1B
Net Calls Change
+$500M
Top Buyers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$268M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.7M |
| 3 |
Two Sigma Advisers
New York
|
+$65.2M |
| 4 |
DA
Duality Advisers
Miami,
Florida
|
+$45.8M |
| 5 |
Two Sigma Investments
New York
|
+$25M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$234M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$232M |
| 3 |
Goldman Sachs
New York
|
-$164M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$92.4M |
| 5 |
JPMorgan Chase & Co
New York
|
-$67.8M |
